Dhir et al. RCT of increasing folic acid from 5-10mg per week to 15-35mg per week if MTX intolerance. No benefit! Although significant placebo response and folic acid is relatively benign. @RheumNow #ACR24 Abstr#0525 https://t.co/D3yfV6a8t6 https://t.co/QpDa1alvMz

• Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patie…
• https://x.com/RichardPAConway/status/1857824199076884798/photo/1

Yokose et al. Population study using NHANES. Gout patients had 1.6 higher fold risk of gallstone disease. What? Why do we care? Well, GLP-1s associated with higher risk gallstones also... @RheumNow #ACR24 Abstr#0133 https://t.co/nf4R0hQe50 https://t.co/wDrEDeNbpT

• The Association Between Gout and Gallstone Disease: US General Population Analy…
• https://x.com/RichardPAConway/status/1857824198754029764/photo/1

🧬 #SLE patients show major community mobility limits: 50% don't leave their neighborhood weekly without help. Life Space Assessment finds lower mobility vs. other chronic conditions. Better mobility linked to higher SES & lower disease activity. @RheumNow #ACR24 abst#0145 https://t.co/2sfXNlJ9JD

• https://x.com/bella_mehta/status/1857823695638564985/photo/1

Data from the French DESIR cohort reveals no significant link between high-dose NSAID use and incident hypertension in patients with axial spondyloarthritis. Two thirds were high dose NSAID users at baseline. Incident hypertension occurred in 11% individuals during follow-up.… https://t.co/EAICDwzxNT

• https://x.com/i/web/status/1857823444974374951

Courvoisier et al. JAK-pot study analysis. Which therapies work quicker in RA? JAKi (as expected) and TNFi (what!?) faster than IL6 and abatacept. @RheumNow #ACR24 Abstr#0501 https://t.co/7DPPwHlqpP https://t.co/3mOJ62hZhp

• How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act i…
• https://x.com/RichardPAConway/status/1857823192204677592/photo/1

Shu et al. Rituximab followed by Telitacicept in refractory/severe APS. Significantly fewer new clinical events in Telitacicept group over 24 weeks (1/21 vs. 6/20) @RheumNow #ACR24 Abstr#0129 https://t.co/hjUQkNNk5w https://t.co/QLQbZ3wQx0

• The Efficacy and Safety of Telitacicept Following Rituximab Immunotherapy on An…
• https://x.com/RichardPAConway/status/1857822940433363387/photo/1

#0585 🔬PsA/axSpA: TNFi Cycling v IL-17Ai Switch ➡️470 pts: Switchers to IL-17Ai had similar/better outcomes v TNFi cyclers @ 6 mo ➡️PsA: Switchers had improved arthritis/psoriasis(-5.0, p=0.02) ➡️axSpA: Switchers had improved fatigue(-9.4, p=0.01) #ACR24 @RheumNow

🔍 Study on lupus & APS highlights key links! APS patients face higher rates of developing SLE, and vice versa. Notable predictors: females, lupus anticoagulant, and specific antibodies. These insights stress the need for vigilant monitoring in both. #ACR24 @RheumNow Abst#0119

Serrano-Combarro et al. Abatacept in RA-ILD. 343 patients. In 23.3% ILD progressed on abatacept. Is that good or bad? We need comparative studies! @RheumNow #ACR24 Abstr#0475 https://t.co/nUEDdjGguA https://t.co/sXEF72MafK

• Rheumatoid Arthritis - Progressive Interstitial Lung Disease with Abatacept: Da…
• https://x.com/RichardPAConway/status/1857821934110572580/photo/1

Are you pts using cannabis? In Canada - 20% reported using w/in past 2 years Use for pain, sleep, anxiety 78% noted efficacy Compare to another study said 57% stopped due to inefficacy, 28% AEs - very diff result 70% did not tell their doc 16S18 @BharatKumarMD #ACR24 @RheumNow https://t.co/6NAECW5MJK

• https://x.com/ericdeinmd/status/1857821449983017045/photo/1
• https://x.com/ericdeinmd/status/1857821449983017045/photo/1

Serrano-Combarro et al. Baricitinib in RA-ILD . 72 patient case series. PFTs in picture. HRCT stable/improved in 72% over 24 months. Dyspnoea stable/improved in 90%. @RheumNow #ACR24 Abstr#0476 https://t.co/aVI2kRZkMN https://t.co/4l5GKsFKtm

• Baricitinib in Rheumatoid Arthritis - Interstitial Lung Disease. National Multi…
• https://x.com/RichardPAConway/status/1857820927368610111/photo/1

Medical cannabis in the USA today Variation in state practice on recreational/medical/decriminalization 16S18 @BharatKumarMD #ACR24 @RheumNow https://t.co/9Ex3lge6KO

• https://x.com/ericdeinmd/status/1857819050316869652/photo/1

PRO-SPIRIT trial data on 1192 PsA pts showed IL-17Ai seemed better than IL-12/23i and IL-23i improving cDAPSA at 3m and as effective as TNFi and JAKi. No much differences seen at 12m. Abst#0076 #ACR24 @RheumNow https://t.co/dScwsmkDOe

• https://x.com/AdelaCastro222/status/1857819668875968932/photo/1

In the SPACE cohort, patients with chronic back pain suspected of axial spondyloarthritis often receive a diagnosis within 35 months from symptom onset. Key determinants for early diagnosis include HLA-B27 positivity and sacroiliitis on imaging. Early diagnosis can be a game… https://t.co/RrcrtRoMfL

• https://x.com/i/web/status/1857819669337678323

#0584🔬Real-World PsA Study:Tofacitinib ➡️141 pts:47% mono,53% combo;~70% on Rx @ 6mo ➡️Similar ⬆️in disease outcomes (cDAPSA LDA: 31% mono vs 21% combo; MDA ~16%). ➡️No significant differences mono v combo outcomes 🩺Tofa effective in diverse PsA population #ACR24 @RheumNow